Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02432560 · ClinicalTrials.gov registry record

Safety and Durability of Sirolimus for Treatment of LAM

A clinical trial of Lymphangioleiomyomatosis, sponsored by University of Cincinnati.

Recruiting
Registry status
600
Enrollment target
20
Study locations

NCT02432560 is a study of Lymphangioleiomyomatosis that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 600 participants, below the 770-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02432560, a study of Lymphangioleiomyomatosis, is actively recruiting participants, sponsored by University of Cincinnati.

RECRUITING
Registry status
600 participants
Enrollment target
20
Study locations

Study Summary

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Conditions Studied

Lymphangioleiomyomatosis

Interventions

  • DRUG Sirolimus
  • DRUG Everolimus

Study Locations (20)

Ohio

  • University of Cincinnati - Cincinnati
  • Cleveland Clinic - Cleveland

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • University of Texas Health Center - Houston

California

  • Stanford University Medical Center - Stanford

Colorado

  • National Jewish Health - Denver

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Loyola University Medical Center, Chicago - Maywood

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2015-03
Est. Completion 2025-07-31

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02432560

The ClinicalTrials.gov registry entry for NCT02432560 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (22% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 2 interventions - of which Sirolimus is the first listed.

NCT02432560 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Ohio, Texas, California.

Frequently Asked Questions

What is clinical trial NCT02432560 about?

NCT02432560 is a clinical study titled "Safety and Durability of Sirolimus for Treatment of LAM". The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or wi...

What is the current status of trial NCT02432560?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2015-03. Estimated completion is 2025-07-31.

What conditions does trial NCT02432560 study?

This clinical trial studies the following conditions: Lymphangioleiomyomatosis.

What interventions are being tested in trial NCT02432560?

The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG).

Who is sponsoring clinical trial NCT02432560?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02432560 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphangioleiomyomatosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphangioleiomyomatosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.